Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [657]

Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for...

Prof Ignace Vergote - UZ Leuven, Leuven, Belgium

Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for metastatic cervical cancer ( Prof Ignace Vergote - UZ Leuven, Leuven, Belgium )

Pembrolizumab plus chemoradiotherapy shows clinically meaningful improvement in...

Prof Domenica Lorusso - Fondazione IRCCS National Cancer Institute, Milan, Italy

Pembrolizumab plus chemoradiotherapy shows clinically meaningful improvement in PFS for locally advanced cervical cancer ( Prof Domenica Lorusso - Fondazione IRCCS National Cancer Institute, Milan, Italy )

Gynaecological Cancers

Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK

Gynaecological Cancers ( Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK )

Atezolizumab with platinum-based CT and niraparib show no improvement in...

Dr Antonio Gonzalez Martin - Cancer Center Clínica Universidad de Navarra...

Atezolizumab with platinum-based CT and niraparib show no improvement in survival for rOC ( Dr Antonio Gonzalez Martin - Cancer Center Clínica Universidad de Navarra, Madrid, Spain )

Induction chemotherapy added to chemoradiation improves PFS and OS in advanced...

Dr Mary McCormack - University College Hospital, London, UK

Induction chemotherapy added to chemoradiation improves PFS and OS in advanced cervical cancer ( Dr Mary McCormack - University College Hospital, London, UK )

Durvalumab addition to chemo shows endometrial cancer benefit

Prof Shannon Westin - University of Texas MD Anderson Cancer Center, Houston...

Durvalumab addition to chemo shows endometrial cancer benefit ( Prof Shannon Westin - University of Texas MD Anderson Cancer Center, Houston, USA )

Part 6: Which different PARP inhibitors are available

Prof Philip Cornford - Royal Liverpool University Hospital, Liverpool, UK

Part 6: Which different PARP inhibitors are available ( Prof Philip Cornford - Royal Liverpool University Hospital, Liverpool, UK )

Part 7: Similarities and Differences

Prof Philip Cornford - Royal Liverpool University Hospital, Liverpool, UK

Part 7: Similarities and Differences ( Prof Philip Cornford - Royal Liverpool University Hospital, Liverpool, UK )

Part 8: How PARP inhibitors are being used now

Prof Philip Cornford - Royal Liverpool University Hospital, Liverpool, UK

Part 8: How PARP inhibitors are being used now ( Prof Philip Cornford - Royal Liverpool University Hospital, Liverpool, UK )

Part 9: What PARP inhibitors mean for the future and what to look out for

Prof Philip Cornford - Royal Liverpool University Hospital, Liverpool, UK

Part 9: What PARP inhibitors mean for the future and what to look out for ( Prof Philip Cornford - Royal Liverpool University Hospital, Liverpool, UK )

The case for investing in women's cancers in Asia Pacific

Dr Heather White - Executive Director, TogetHER for Health

The case for investing in women's cancers in Asia Pacific ( Dr Heather White - Executive Director, TogetHER for Health )

Nigeria solidarity support fund and the annual youth engagement campaign on HPV

Dr Fejiro Chinye-Nwoko - CEO, Nigeria Solidarity Support Fund, Lagos, Nigeria

Nigeria solidarity support fund and the annual youth engagement campaign on HPV ( Dr Fejiro Chinye-Nwoko - CEO, Nigeria Solidarity Support Fund, Lagos, Nigeria )

More from ecancer